CER budgets heading up in '12

More than half of drug companies plan to increase spending for market-access activities in 2012, including comparative effectiveness research (CER), according to a report from Cutting Edge Information.

Responding to payer demands for outcomes, virtually all drug research companies expect to at least maintain spend across most market-access categories, the benchmarking study showed.

Growth areas include health economics and outcomes research (64% of firms plan to increase funding), as well as patient-reported-outcomes activities, pegged by 57% of respondents for more spend, and CER, which half of firms anticipate upping their spend for.

Across all market access activities studied, pricing teams' budgets will largely remain the same. And according to the study, 73% of companies will hold their pricing budgets steady next year.

Cutting Edge talked to 20 companies for its study, said Elio Evangelista, director of research for the firm.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.